Skip to content

Enterprise value at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$16.77B+178%
Revvity logo
RevvityRVTY
$12.88B-13.7%
Incyte logo
IncyteINCY
$15.31B+55.9%
Roivant Sciences logo
Roivant SciencesROIV
$18.51B+157%
Gilead Sciences logo
Gilead SciencesGILD
$187.53B+19.7%
AbbVie logo
AbbVieABBV
$460.96B+24.7%

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$10.26B+45.4%
P/E45.6×-11.3×
P/S24.6×+3.4×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0.0×
Current ratio9.5×-0.2×

Where this comes from

Calculated from Krystal Biotech, Inc.’s reported figures.

The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Krystal Biotech, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Krystal Biotech, Inc.'s enterprise value?
Krystal Biotech, Inc. (KRYS) reported enterprise value of $7.06B in Q1 2026.
How has Krystal Biotech, Inc.'s enterprise value changed year-over-year?
Krystal Biotech, Inc.'s enterprise value increased by 44.2% year-over-year, from $4.89B to $7.06B.
What is the long-term trend for Krystal Biotech, Inc.'s enterprise value?
Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s enterprise value has grown at a 40.2% compound annual growth rate (CAGR), from $1.23B to $6.66B.
What does enterprise value mean?
What it would cost to buy the entire business, debt included and cash netted out.
How do you interpret enterprise value?
The capital-structure-neutral valuation base — used in EV/EBITDA and EV/Sales to compare companies with different leverage on a like-for-like footing.
How does enterprise value compare across companies?
Comparable across non-financial companies via the EV multiples it feeds; not used for banks and insurers.